Did EQRx underestimate all the hurdles to disrupt the US drug pricing from the get-go?
Or its ambition was really crushed by unexpected external forces?
I personally applaud EQRx's ambition, but feel they underestimated all the hurdles and regulatory / geo-political risks to their value proposition.

Comentários